Back

Apabetalone (RVX-208) inhibits key drivers of vascular inflammation, calcification, and plaque vulnerability through a BET-dependent epigenetic mechanism

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 6 - Coronary artery disease inflammation Inflammation and Immunity ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Ewelina Kulikowski

Calgary (Canada)

10 More presentations in this session

Presentation thumbnail
Inflammation implicated in the aetiology of major vascular and non-vascular diseases in East Asians
Doctor M. Karim (Oxford, GB)
Abstract Slides
Presentation thumbnail
Proprotein convertase subtilisin/kexin 9 (PCSK9) and lipopolysaccharide (LPS) in patients with atrial fibrillation. A biomarker post-hoc analysis from the ATHERO-AF cohort.
Professor P. Pignatelli Spinazzola (Rome, IT)
Abstract Slides
Presentation thumbnail
Growth differentiation factor-15 and mortality in suspected or known coronary heart disease patients with chronic kidney disease: a subanalysis of the ANOX study
Doctor D. Takagi (Kyouto, JP)
Abstract
Presentation thumbnail
Impact of CD14++CD16+ monocytes on coronary plaque vulnerability assessed by optical coherence tomography in coronary artery disease patients
Doctor H. Yamamoto (Kobe, JP)
Abstract Slides
Presentation thumbnail
High plasma sRAGE is associated with slower carotid intima media thickness progression and lower risk for first-time coronary events and mortality
Mrs H. Grauen Larsen (Malmo, SE)
Abstract

Access the full session

Session thumbnail
Poster Session 6 - Coronary artery disease inflammation

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources